FDMT 4D Molecular Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FDMT

Price (delayed)

$10.02

Market cap

$523.81M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.57

Enterprise value

$471.86M

?
Relative Growth: Rel. Growth: 65
Relative Strength: Rel. Strength: 83
Relative Valuation: Rel. Valuation: 10
Relative Profitability: Rel. Profitability: 37

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector ...

Highlights
The company's debt fell by 14% YoY and by 4.1% QoQ
The gross profit has increased by 3.6% since the previous quarter
4D Molecular Therapeutics's EPS has increased by 19% YoY but it has decreased by 6% from the previous quarter
The company's net income fell by 15% QoQ but it rose by 9% YoY
FDMT's quick ratio is down by 25% YoY
The company's equity fell by 11% QoQ and by 3.8% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.4dmoleculartherapeutics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of FDMT

FDMT stock price

How has the 4D Molecular Therapeutics stock price performed over time
Intraday
5.14%
1 week
11.71%
1 month
6.14%
1 year
161.62%
YTD
33.6%
QTD
7.63%

Financial performance

How have 4D Molecular Therapeutics's revenue and profit performed over time
Revenue
$88.24M
Gross profit
$88.24M
Operating income
-$179.55M
Net income
-$160.9M
Gross margin
100%
Net margin
-182.3%
The company's net margin has surged by 100% YoY but it fell by 11% QoQ
The operating margin has soared by 100% YoY but it has contracted by 9% from the previous quarter
The company's net income fell by 15% QoQ but it rose by 9% YoY
The operating income is down by 13% QoQ but it is up by 12% YoY

Price vs fundamentals

How does FDMT's price correlate with its fundamentals

Growth

What is 4D Molecular Therapeutics's growth rate over time

Valuation

What is 4D Molecular Therapeutics stock price valuation
P/E
N/A
P/B
1.13
P/S
7.73
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.35
4D Molecular Therapeutics's EPS has increased by 19% YoY but it has decreased by 6% from the previous quarter
The stock's P/B is 36% below its 5-year quarterly average of 1.7 but 20% above its last 4 quarters average of 0.9
The company's equity fell by 11% QoQ and by 3.8% YoY
The P/S is 100% lower than the 5-year quarterly average of 3148.4 and 100% lower than the last 4 quarters average of 2591.1
FDMT's revenue is up by 3.6% since the previous quarter

Efficiency

How efficient is 4D Molecular Therapeutics business performance
4D Molecular Therapeutics's ROS has soared by 100% YoY but it has decreased by 11% from the previous quarter
The return on equity has declined by 16% since the previous quarter and by 11% year-on-year
The ROA has contracted by 15% from the previous quarter and by 6% YoY
The return on invested capital has declined by 12% since the previous quarter but it rose by 10% year-on-year

Dividends

What is FDMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FDMT.

Financial health

How did 4D Molecular Therapeutics financials performed over time
The total liabilities has grown by 33% YoY
FDMT's quick ratio is down by 25% YoY
The company's debt is 95% lower than its equity
FDMT's debt to equity is up by 25% since the previous quarter
The company's debt fell by 14% YoY and by 4.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.